Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Sinew Pharma's Enterprise Value is NT$3,301.46 Mil.
Sinew Pharma's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-117.31 Mil. Therefore, Sinew Pharma's EV-to-EBIT ratio for today is -28.14.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Sinew Pharma's Enterprise Value is NT$3,301.46 Mil.
Sinew Pharma's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-105.71 Mil. Therefore, Sinew Pharma's EV-to-EBITDA ratio for today is -31.23.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Sinew Pharma's Enterprise Value is NT$3,301.46 Mil.
Sinew Pharma's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 was NT$0.00 Mil. Therefore, Sinew Pharma's EV-to-Revenue ratio for today is .
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Sinew Pharma's Enterprise Value is NT$3,301.46 Mil.
Sinew Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-99.78 Mil. Therefore, Sinew Pharma's EV-to-FCF ratio for today is -33.09.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Sinew Pharma (ROCO:6634) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Sinew Pharma's current Enterprise Value is NT$3,301.46 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Sinew Pharma's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-117.31 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Sinew Pharma's current Enterprise Value is NT$3,301.46 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Sinew Pharma's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-105.71 Mil.
Sinew Pharma's current Enterprise Value is NT$3,301.46 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Sinew Pharma's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 was NT$0.00 Mil.
Sinew Pharma's current Enterprise Value is NT$3,301.46 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Sinew Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-97.67 Mil.
Sinew Pharma's current Enterprise Value is NT$3,301.46 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Sinew Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-99.78 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinew Pharma Enterprise Value Related Terms
Sinew Pharma Enterprise Value Historical Data
* Premium members only.
The historical data trend for Sinew Pharma's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6634 vs VRTX, REGN, RVMD: Enterprise Value Comparison
For the Biotechnology subindustry, Sinew Pharma's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinew Pharma Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sinew Pharma's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Sinew Pharma's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Sinew Pharma's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of NT$3,301.46 Mil mean?
Sinew Pharma (ROCO:6634) has a Enterprise Value of NT$3,301.46 Mil as of Aug. 23, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Sinew Pharma and its competitors.
Is Sinew Pharma's Enterprise Value too high?
Sinew Pharma's current Enterprise Value is NT$3,301.46 Mil. Overall, Sinew Pharma has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Sinew Pharma's Enterprise Value compare to VRTX and REGN?
Sinew Pharma's Enterprise Value of NT$3,301.46 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Sinew Pharma and its competitors. Sinew Pharma's current Enterprise Value is NT$3,301.46 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinew Pharma stock overvalued right now?
Sinew Pharma (ROCO:6634) has a current Enterprise Value of NT$3,301.46 Mil. The current Enterprise Value is NT$3,301.46 Mil. Sinew Pharma's overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Sinew Pharma (ROCO:6634), the current Enterprise Value is NT$3,301.46 Mil as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sinew Pharma Inc is a Taiwan-based biopharmaceutical company. The company is mainly engaged in the research and development of new drugs for the treatment of liver diseases and pain relief. Its drug candidates includes SNP-610, SNP-630, SNP-810, SNP-820, SNP-830 and SNP-840.
25GF Score
Get the complete analysis for ROCO:6634
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6634 has been successfully added to your 
